Effects of furosemide, torasemide and controlled fluid intake on perfluoroisobutene induced lung oedema and mortality.
Permeability type lung oedema has been induced in rats by exposing them to the lung oedemagen perfluoroisobutene (PFIB). The loop diuretic furosemide (CAS 54-31-9) reduces the lung oedema and the pattern and severity of the pathological changes associated with inhalation of PFIB (mean Ct 945 mg.min.m-3) and delays the time to death following inhalation of an LCt65 equivalent of the gas. Combined administration of the loop diuretic torasemide (CAS 56211-40-6) and water deprivation reduces PFIB induced oedema and mortality during the treatment period (24 h). Controlling the intake of fluids after treatment prevents the rapid increase in oedema and mortality which occurs when water is returned ad libitum. Torasemide and water deprivation followed by controlled fluid intake delays but does not reduce the overall mortality due to an LCt70 of PFIB.
Onyefuru
L C
LC
Medical Countermeasures (Biology), Chemical and Biological Defence Establishment (CBDE), Salisbury, Wiltshire, UK.
Upshall
D G
DG
Rice
P
P
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004232:Diuretics / Q000627:therapeutic use*; D004326:Drinking; D005260:Female; D005466:Fluorocarbons / Q000633:toxicity; D005665:Furosemide / Q000627:therapeutic use*; D006400:Hematocrit; D008168:Lung / Q000473:pathology; D009206:Myocardium / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D011654:Pulmonary Edema / Q000139:chemically induced / Q000401:mortality / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides / Q000627:therapeutic use*; D000077786:Torsemide
D004232:Diuretics; D005466:Fluorocarbons; D013449:Sulfonamides; C016648:perfluoroisobutylene; D005665:Furosemide; D000077786:Torsemide